Do We Need to Taper Down Steroid Therapy for Bell's Palsy
NCT04406376 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 124
Last updated 2020-07-28
Summary
Bell's palsy \[BP\] is defined as acute idiopathic peripheral facial palsy or paralysis.
Additional symptoms frequently include pain around or behind the ear, impaired tolerance to ordinary levels of noise and disturbed sense of taste on the same side. It affects men and women more or less equally.
There is a consensus in the literature regarding the importance of steroid treatment for improving recovery rates and sequela of BP. Moreover, there is increasing level of high quality of evidence in recent years for a combined antiviral and steroids treatment for severe BP (House Brackmann \[HB\] 5-6).
Adverse effects (AEs) were reported in 1-12% of patients treated with steroids, antivirals or placebo. The AEs reported were dyspepsia, loss of blood sugar control, headache, fatigue, dizziness and insomnia, recurrent duodenal ulcers, mood swings, and acute psychosis. All effects resolved when treatment was stopped.
Although steroid and antivirals are widely used for BP, there is a high variability of steroids treatment, both in the dosage given and in the way of tapering down.
Among the different steroid regimens used were: prednisone 1 mg/kg for 5 days tapered to 10 mg/day for remaining 5 days; prednisone (1 mg/kg for 10 days then tapered to zero over the next 6 days); prednisolone 60 mg for 5 days, 30 mg for 3 days, and 10 mg for 2 days.
House-Brackmann (HB) system is widely used for facial function assessment. It is based on a six-grade score, where grade I is normal function, grade VI is complete absence of facial motor function, and grades II to V are intermediate.
Steroid-induced side effects generally require tapering of the drug as soon as the disease being treated is under control. Tapering must be done carefully to avoid both recurrent activity of the underlying disease and possible cortisol deficiency resulting from hypothalamic-pituitary-adrenal axis (HPA) suppression. However, according to a review by Furst et al (2019), a patient who has received any dose of glucocorticoid for less than 3 weeks or patients treated with alternate-day prednisone at a dose of less than 10 mg (or its equivalent) are unlikely for HPA suppression. They concluded that short-term glucocorticoid therapy (up to three weeks), even if at a fairly high dose, can simply be stopped and need not to be tapered..
According to the above, the investigators assume that a rapid withdrawal of steroids after short course of treatment for BP should neither influence the efficacy or safety of treatment.
Finally, steroid regimen may be hard to follow for some patients and can results in confusion and frustration. Simplifying steroid regimen, such as skipping withdrawal if not necessary, may solve this problem.
The objective of our study is to determine the effectiveness and safety of prednisone treatment with no tapering down for Bell's Palsy.
Conditions
- Bell Palsy
Interventions
- DRUG
-
Prednisone tablet
Treatment of Bell's Palsy with prednisone, with or without tapering down.
Sponsors & Collaborators
-
Carmel Medical Center
lead OTHER
Principal Investigators
-
Yoav Yanir, MD · Carmel Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-12
- Primary Completion
- 2023-05-01
- Completion
- 2023-08-01
Countries
- Israel
Study Locations
More Related Trials
-
OTO-104 for Meniere's Disease
NCT01084525 ·Status: COMPLETED ·Phase: PHASE1
-
Fludrocortisone for Sudden Hearing Loss
NCT01186185 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease
NCT00802529 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Autoimmunity in Inner Ear Disease
NCT00000361 ·Status: TERMINATED ·Phase: PHASE3
-
Effects of Endolymphatic Sac Drainage With Steroids for Meniere's Disease
NCT00500474 ·Status: COMPLETED ·Phase: NA
-
Intracochlear Injection of Glucocorticoid
NCT07134075 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Prevention of Noise-induced Hearing Loss
NCT02049073 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes
NCT02286960 ·Status: COMPLETED ·Phase: PHASE4
-
Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays
NCT00279916 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Statins and Protection From Hearing Loss
NCT04826237 ·Status: RECRUITING ·Phase: PHASE4
-
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
NCT03255473 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
NCT02612337 ·Status: COMPLETED ·Phase: PHASE3
-
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
NCT02717442 ·Status: TERMINATED ·Phase: PHASE3
-
Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection
NCT04794842 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease
NCT05851508 ·Status: RECRUITING ·Phase: PHASE3
-
The Efficacy of Steroid Therapy in Vestibular Neuritis
NCT02098330 ·Status: COMPLETED ·Phase: PHASE3
-
Stress Management Therapy for Meniere's Disease
NCT01099046 ·Status: UNKNOWN ·Phase: NA
-
Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss
NCT06968507 ·Status: RECRUITING ·Phase: PHASE4
-
Short-term Oral Prednisone for Acute Subjective Tinnitus
NCT05591144 ·Status: COMPLETED ·Phase: NA
-
Acute Otitis Media: Adjuvant Therapy to Improve Outcome
NCT00000363 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of the Treatment of Chronic Laryngitis With Amitryptiline
NCT02434523 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A 6-Month Extension Study of OTO-104 in Meniere's Disease
NCT02768662 ·Status: TERMINATED ·Phase: PHASE3
-
OTO-104 for the Treatment of Meniere's Disease
NCT01412177 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of a Mastoid Device in Subjects With Ménière's Disease
NCT03520322 ·Status: TERMINATED ·Phase: NA
-
Vestibular Rehabilitation With Intratympanic Drug Therapy in Meniere's Disease
NCT05355610 ·Status: UNKNOWN ·Phase: NA